Involvement of 5-lipoxygenase activating protein in the amyloidotic phenotype of an Alzheimer's disease mouse model.
(1/4)
(+info)
Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti-inflammatory 5-lipoxygenase-activating protein inhibitor.
(2/4)
(+info)
An inhibitor of leukotriene synthesis affects vasopressin secretion following osmotic stimulus in rats.
(3/4)
(+info)
FLAP pharmacological blockade modulates metabolism of endogenous tau in vivo .
(4/4)
(+info)